The digital pathology software developer is raising funding that would help it to increase its headcount and support its Aiosyn Mitosis Breast application.

Demand remains low, but lab stakeholders said the industry is significantly better prepared to meet a spike in H5N1 testing needs than it was during the COVID-19 pandemic.